Jayasree Iyer – CEO, Access to Medicine Foundation
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Address: Wilgenlaan 5 • 1161 JK Zwanenburg,Netherlands
Tel: 31 (0) 20 / 407 20 72
Web: http://www.daiichi-sankyo.nl/
DAIICHI SANKYO’s goal is to establish itself as a ‘Global Pharma Innovator.’ The pharmaceutical industry is one of the 21st century’s growth industries, and what this vision of the company signifies is DAIICHI SANKYO making it the leading industry of Japan, a nation built on the platform of scientific and technological creativity, and establishing itself as a firm presence by continued success as a flagship company. This is the vision that guides the development of our global pharmaceutical operations.
DAIICHI SANKYO’s products are used not only in Japan but also in many parts of the world including Asia, Europe and the United States. To pick up on global needs all over the world and have these reflected in global pharmaceutical operations, we are active in promoting information exchange in a number of areas including research and development, supply chain management and marketing.
We are determined to contribute to the health of people everywhere by creating new medicines in popular use throughout the world, and delivering them to places where medical treatment is required, transcending national borders.
We have about 2,300 overseas medical representatives in 33 locations, mainly in Europe and the United States. From this point on, we are aiming for growth through our own development and sales, mainly in the United States, and to this end, we are planning to expand our overseas development and sales bases. While making efforts to develop innovative new medicines, we have become established as a firm presence in the global market for pharmaceutical products by implementing the highest standard of operational efficiency in the industry in order to ‘respond to the medical needs of people everywhere.’
Our U.S. subsidiary, Daiichi Sankyo, Inc. (DSI) has research and development and sales sections, and as the organization that forms the nucleus of our U.S. operations, is expected to grow in the future.
Our European subsidiary, Daiichi Sankyo Europe GmbH (DSE), is headquartered in Munich, Germany, and has around 800 medical representatives in operational bases in 10 European countries.
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here
